SERS-based immunoassay using core–shell nanotags and magnetic separation for rapid and sensitive detection of cTnI

Hu, Cunming; Ma, Li; Mi, Fang; Guan, Ming; Guo, Chang; Peng, Fei; Sun, Shijiao; Wang, Xiaomei; Liu, Tingwei; Li, Jiutong

doi:10.1039/d0nj05774f

Cited by 29 publications

(14 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With this methodology, the increase in cTnI concentration increases the density of the signal probes on the surface of the magnetic beads, resulting in an enlargement of the SERS signal from the reporter molecule that allowed the biomarker quantification. Hu et al (2021) reported a proposal performing the immunoassay and the Raman measurements in the same container. The detection probes consisted of a monoclonal antibody-conjugated on gold-silver core-shell nanoparticles with 4MBA encapsulated between the two metals (cTnI-mAb-Au@4MBA@Ag).…”

Section: Label Free and Label Based Determination Of Ctni By Surface ...mentioning

confidence: 99%

See 1 more Smart Citation

A review of cardiac troponin I detection by surface enhanced Raman spectroscopy: Under the spotlight of point-of-care testing

Saviñon-Flores

Trejo

et al. 2022

Front. Chem.

View full text Add to dashboard Cite

Cardiac troponin I (cTnI) is a biomarker widely related to acute myocardial infarction (AMI), one of the leading causes of death around the world. Point-of-care testing (POCT) of cTnI not only demands a short turnaround time for its detection but the highest accuracy levels to set expeditious and adequate clinical decisions. The analytical technique Surface-enhanced Raman spectroscopy (SERS) possesses several properties that tailor to the POCT format, such as its flexibility to couple with rapid assay platforms like microfluidics and paper-based immunoassays. Here, we analyze the strategies used for the detection of cTnI by SERS considering POCT requirements. From the detection ranges reported in the reviewed literature, we suggest the diseases other than AMI that could be diagnosed with this technique. For this, a section with information about cardiac and non-cardiac diseases with cTnI release, including their release kinetics or cut-off values are presented. Likewise, POCT features, the use of SERS as a POCT technique, and the biochemistry of cTnI are discussed. The information provided in this review allowed the identification of strengths and lacks of the available SERS-based point-of-care tests for cTnI and the disclosing of requirements for future assays design.

show abstract

Section: Label Free and Label Based Determination Of Ctni By Surface ...mentioning

confidence: 99%

“… Schematic representation of different cTnI detection systems working in solution. (A) sandwich immunoassay, adapted from Hu et al (2021) and (B) 3D AuNPs-PEN substrate, adapted from Lee et al (2022) . …”

Section: Label Free and Label Based Determination Of Ctni By Surface ...mentioning

confidence: 99%

A review of cardiac troponin I detection by surface enhanced Raman spectroscopy: Under the spotlight of point-of-care testing

Saviñon-Flores

Trejo

et al. 2022

Front. Chem.

View full text Add to dashboard Cite

show abstract

“…The proposed immunoassay demonstrated high specificity and sensitivity, being able to detect both H-FABP and cTnI in ultralow concentrations such as 0.6396 and 0.0044 ng/mL, respectively, hence promoting its implementation for an accurate diagnosis of AMI. Later on, based on the same principle, the group achieved a LOD of 9.8 pg/mL of cTnI, which is considerably lower than the approved cTnI threshold for the diagnosis of cardiac diseases, by using core-shell nanotags and a magnetic separation based SERS immunoassay by employing 4-mercaptobenzoic acid as an active Raman reporter, thus achieving a diagnostic tool with advantages such as specificity, ultrasensitivity, reduced costs of fabrication, ease-of-use, and no sample pre-treatment with promising reliability and stability [ 39 ].…”

Section: Surface Enhanced Raman Spectroscopy (Sers) Sensing Platformsmentioning

confidence: 99%

Cardiac Troponin Biosensor Designs: Current Developments and Remaining Challenges

Campu

Muresan

Craciun

et al. 2022

IJMS

View full text Add to dashboard Cite

Acute myocardial infarction (AMI) is considered as one of the main causes of death, threating human lives for decades. Currently, its diagnosis relies on electrocardiography (ECG), which has been proven to be insufficient. In this context, the efficient detection of cardiac biomarkers was proposed to overcome the limitations of ECG. In particular, the measurement of troponins, specifically cardiac troponin I (cTnI) and cardiac troponin T (cTnT), has proven to be superior in terms of sensitivity and specificity in the diagnosis of myocardial damage. As one of the most life-threatening conditions, specific and sensitive investigation methods that are fast, universally available, and cost-efficient to allow for early initiation of evidence-based, living-saving treatment are desired. In this review, we aim to present and discuss the major breakthroughs made in the development of cTnI and cTnT specific biosensor designs and analytical tools, highlighting the achieved progress as well as the remaining challenges to reach the technological goal of simple, specific, cheap, and portable testing chips for the rapid and efficient on-site detection of cardiac cTnI/cTnT biomarkers in order to diagnose and treat cardiovascular diseases at an incipient stage.

show abstract

“…Table 1 summarizes a series of various biosensing technologies for cTnI that have been reported in recent years [31][32][33][34][35][36]. Compared with the existing and emerging biosensors, the packaged thin-walled microbubble biosensor has a lager measure range and lower DL of cTnI.…”

Section: Detection Of Ctnimentioning

confidence: 99%

Label‐free detection of cardiac troponin‐I with packaged thin‐walled microbubble resonators

Guo

Zhao

Zhou

et al. 2022

Journal of Biophotonics

View full text Add to dashboard Cite

The measurement of cardiac troponin‐I (cTnI) is widely used for diagnosing acute myocardial infarction (AMI) diseases because of its myocardial specificity. Packaged microbubble resonators with thin wall are utilized for label‐free and specific detection of cTnI based on whispering gallery mode (WGM). This packaged structure can provide a good protection for the biosensor, improve the anti‐interference ability of the sensor and reduce the system noise. The theoretical detection limit of the biosensors for cTnI in phosphate buffer saline (PBS) is 0.4 ag mL−1 (0.02 aM). Furthermore, we demonstrated that the biosensors can be used to detect cTnI molecules in simulated serum and the theoretical detection limit is also 0.4 ag mL−1 (0.02 aM). These results are much far below the clinical cut‐off value and show a huge application potential for the detection of cardiac biomarkers of AMI.

show abstract

SERS-based immunoassay using core–shell nanotags and magnetic separation for rapid and sensitive detection of cTnI

Abstract: Au-4MBA@Ag with a strong Raman signal was successfully synthesized, and combination with magnetic separation technology achieved sensitive detection of cTnI.

Cited by 29 publications

References 38 publications

A review of cardiac troponin I detection by surface enhanced Raman spectroscopy: Under the spotlight of point-of-care testing

A review of cardiac troponin I detection by surface enhanced Raman spectroscopy: Under the spotlight of point-of-care testing

Cardiac Troponin Biosensor Designs: Current Developments and Remaining Challenges

Label‐free detection of cardiac troponin‐I with packaged thin‐walled microbubble resonators

Contact Info

Product

Resources

About